Dual Antiplatelet Therapy After Acute Coronary Syndrome
Listen now
Description
Dual antiplatelet therapy, typically aspirin and an oral P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor, cangrelor), reduces adverse events after acute coronary syndrome (ACS) but choice of agent and optimal duration may be patient-specific. Umair Khalid, MD, a cardiologist at the Baylor School of Medicine in Houston, discusses how to use these agents in management of ACS.
Related Article(s):
Oral Antiplatelet Therapy After Acute Coronary Syndrome
More Episodes
Interstitial lung disease (ILD), characterized by inflammation and fibrosis of the lungs, is associated with progressive dyspnea and results in approximately 25 000 to 30 000 deaths in the US each year. Toby M. Maher, MD, MSc, PhD, of Keck Medicine of USC, discusses the diagnosis and management...
Published 04/22/24
Published 04/22/24
Dislocated hips in newborns can lead to complex surgery, interruption to family life, and premature osteoarthritis. Daniel Perry, MBChb(Hons), PhD, of Alder Hey Children's Hospital, University of Liverpool, discusses the clinical diagnosis of dislocated hips in newborns with JAMA Associate Editor...
Published 04/15/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
